The PDHA Urges FDA to Ban Mercury Amalgam Fillings & Support Ethical Dentists

SAN DIEGO, CA, UNITED STATES, August 1, 2025 /EINPresswire.com/ — The Preventive Dental Health Association (PDHA) urgently calls on the U.S. Food and Drug Administration (FDA) to ban mercury amalgam fillings, often referred to as “silver fillings,” which contains approximately 50% mercury, a known neurotoxin.

mercury amalgam fillings
Silver fillings are actually 50% elemental mercury.


A 2025 mini-review by Blanche D. Grube, DMD, and Anita Vazquez Tibau, Will the US Food and Drug Administration (FDA) Follow the EU’s Mercury Dental Amalgam Ban? A Mini-Review, highlights the FDA’s decision in 2009 that a ban of, or restriction on, the use of dental amalgam was not necessary or appropriate. The PDHA believes this unrestricted approach fails to align with recent scientific evidence indicating mercury exposures from amalgam exceed safety levels and pose a serious health risk.

Mercury amalgam releases toxic vapors with every breath, chew, or swallow, making it the primary source of human mercury exposure, per the World Health Organization. Over 180 million Americans who have mercury fillings, may eventually have them removed, vastly exceeding EPA safety thresholds. This added exposure during removal greatly increases the risks of neurological, kidney, or immune system issues. Pregnant women, children, and those with genetic vulnerabilities are especially at risk. Meanwhile, the American Dental Association’s (ADA) defense of amalgam’s cost-effectiveness fuels the FDA’s resistance to bans and transparency, while ethical dentists face relentless persecution for prioritizing patient safety.

Pregnant women, children, and those with genetic vulnerabilities are especially at risk.


The PDHA would like to highlight the challenges faced by ethical dentists who choose mercury-free practices and prioritize safe removal with full informed consent. These professionals routinely encounter scrutiny, including license reviews, from dental boards influenced by the ADA, which supports amalgam use. The PDHA invites public support for citizen petition FDA-2025-P-2526-0001 to protect millions, including veterans and military personnel, from potential harm.

Globally, safer alternatives like composite resin and Atraumatic Restorative Treatment are widely used, and the European Union’s 2025 amalgam ban, aligned with the Minamata Convention, sets a precedent. U.S. dental practices contribute to environmental mercury pollution and the PDHA urges adoption of safe removal protocols like the PROTECT and SMART Protocols. The Grube-Tibau mini-review, underscores the need for updated FDA policies.

The PDHA requests the public:
• Support for the citizen petition FDA-2025-P-2526-0001 by August 31, 2025, at regulations.gov and submit a comment in the comment box stating, “I support the ban on mercury dental amalgam and the protection of ethical dentists.” to demand the FDA eliminate this neurotoxin and end the persecution of dentists using safe, non-toxic practices.
• Read and share the mini-review at scivisionpub.com to raise awareness.
• Encourage new FDA leadership to align with precedents like the ban on mercury-based thimerosal in vaccines and phase out mercury amalgam.
• Support mercury-free dentists using PROTECT or SMART protocols.

The PDHA stands with veterans, families, and ethical dentists to promote safer dental care. We invite the FDA to collaborate on this critical public health issue.

David Kennedy
The Preventive Dental Health Association
+1 619-247-5738

Check Out: PDHA urges adoption of safe removal protocols like the PROTECT Protocol

Read full Press Release Here

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Pinterest

How a Study Became a Regulatory Benchmark – and Why the Ground Has Shifted

In 2006, FDA staff prepared a White Paper concerning potential adverse health risks associated with mercury in dental amalgam. The agency then brought the issue before a joint advisory panel in September 2006. The panel did not simply endorse the FDA staff’s conclusion. According to the contemporaneous record, the panel voted 13–7 against accepting the FDA staff’s safety conclusion.

Learn More »

The Evidence That Never Made the Headlines: Revisiting the Casa Pia Mercury Trial

One of the most important documents I obtained through the Freedom of Information Act is a September 15, 1999 Report to the Data and Safety Monitoring Board for the Casa Pia Children’s Amalgam Trial. This document was written while the trial was still underway. It is not a retrospective interpretation. It is a contemporaneous report from the investigators to the body charged with monitoring the safety of the study.

Learn More »